SequelSEC

ALNYLAM PHARMACEUTICALS, INC. ALNY

Pharmaceutical Preparations · CIK 0001178670 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.71B
Fiscal year ended 2025-12-31
Operating income
$501.58M
Fiscal year ended 2025-12-31
Free cash flow
$465.38M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$42.63BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$321.44Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income135.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue11.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity54.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Operating margin13.5%89th
Net margin8.4%83th
FCF margin12.5%81th
Revenue YoY growth65.2%78th
Effective tax rate2.9%29th
Gross margin81.8%70th
R&D / revenue35.5%31th
SBC / revenue9.4%33th
Current ratio2.76x39th
CapEx / revenue1.6%47th

ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported revenue of $3.71B and net income of $313.75M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ALNYLAM PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ALNYLAM PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$3.71B
Cost of revenue$677.17M
Gross profit$3.04B
Operating income$501.58M
Net income$313.75M
Research & development$1.32B
Weighted-average diluted sharesUnavailable
Pretax income$323.15M
Income tax expense$9.40M
Diluted EPSUnavailable
Selling, general & administrative$1.21B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

ALNYLAM PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$1.66B
Total assets$4.97B
Current assets$4.05B
Total liabilities$4.18B
Current liabilities$1.47B
Total equity incl. NCI$789.18M
Temporary (mezzanine) equityUnavailable
Inventory$82.72M
Accounts receivable$777.57M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$115.72M

Cash flow

ALNYLAM PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow$524.08M
Capital expenditures$58.70M
Investing cash flow$436.33M
Financing cash flow-$305.19M
Net change in cash$690.16M
Stock-based compensation$348.24M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$55.66M

Derived

ALNYLAM PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow$465.38M
Gross margin81.8%
Operating margin13.5%
FCF margin12.5%
SBC / revenue9.4%
Current ratio2.76x
Revenue YoY growth65.2%
Net margin8.4%
R&D / revenue35.5%
CapEx / revenue1.6%
Long-term debt / equityUnavailable
Effective tax rate2.9%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALNY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-07-30View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.